Company: NCEL
Filing Date: 2025-03-31
Form Type: 425
Source: 0001213900-25-025889
Chunk: 92

Company: NewcelX Ltd.
Filing Date: 2025-03-31
Form: 425
Chunk 92
---
, price/volume amounts, the amount of Common Shares identified in this Agreement, Conversion Price, Exercise Price,
Underlying Shares and similar figures in the Transaction Documents shall be equitably adjusted (but without duplication) to offset the
effect of stock splits, similar events and as otherwise described in the Transaction Documents.

<div align='center'>(Signature Pages Follow)

48</div>

IN WITNESS WHEREOF, the parties
hereto have caused this Securities Purchase Agreement to be duly executed by their respective authorized signatories as of the date first
indicated above.

| NLS PHARMACEUTICS LTD. |        |                 |
| By:                    |        |                 |
|                        | Name:  | Alexander Zwyer |
|                        | Title: | CEO             |

<div align='center'>[REMAINDER OF PAGE INTENTIONALLY LEFT BLANK

SIGNATURE PAGE FOR PURCHASER FOLLOWS]

49

[PURCHASER SIGNATURE PAGE TO NLS PHARMACEUTICS LTD.

SECURITIES PURCHASE AGREEMENT]</div>

IN WITNESS WHEREOF, the undersigned have caused
this Securities Purchase Agreement to be duly executed by their respective authorized signatories as of the date first indicated above.

Name of Purchaser: __________________________________

Signature of Authorized Signatory of Purchaser: _________________________________________

Name of Authorized Signatory: __________________________________________

Title of Authorized Signatory: _________________________________________

Email Address of Authorized Signatory: _____________________________

Facsimile Number of Authorized Signatory: ____________________________________________

State of Incorporation of Purchaser: ___________________________________________

Address for Notice to Purchaser:

Address for Delivery of Securities to Purchaser (if not same as address
for notice):

Initial Closing Subscription Amount:

Initial Closing Preferred Shares: 757,576

Initial Closing Warrant: 492,424

Subsequent Closing Subscription Amount:

Subsequent Closing Preferred Shares: 378,788

Subsequent Closing Warrants: 246,212

EIN Number, if applicable, will be provided under separate cover

<div align='center'>50

[PURCHASER SIGNATURE PAGE TO NLS PHARMACEUTICS LTD.

SECURITIES PURCHASE AGREEMENT]</div>

IN WITNESS WHEREOF, the undersigned have caused
this Securities Purchase Agreement to be duly executed by their respective authorized signatories as of the date first indicated above.

Name of Purchaser: __________________________________

Signature of Authorized Signatory of Purchaser: _________________________________________

Name of Authorized Signatory: